Evaluation Navigating the Spectrum of Bipolar Disorder: New Options with Novel Mechanisms of Action Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). JULIE CARBRAY, PHD, FPMHNP-BC, PMHCNS-BC, APRN 5 4 3 2 1 VERONICA RIDPATH, DO 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Summarize the challenges associated with recognition and diagnosis/classification of BD, including distinguishing it from other mental health conditions and accurately characterizing its features 5 4 3 2 1 Describe the burden of cardiometabolic symptoms, such as weight gain, and other AEs associated with conventional BD treatments, and their impact on patient outcomes 5 4 3 2 1 Evaluate the MOAs associated with newer and novel treatment options and their potential to address unmet needs 5 4 3 2 1 Discuss the safety and efficacy of newer and novel agents for BD management and their respective treatment implications, including their potential to mitigate AEs and/or address specific BD features 5 4 3 2 1 Implement appropriate patient-centered strategies for BD management to improve treatment outcomes and patient QoL 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with Bipolar on a monthly basis? 10 or fewer 20 30 40 50 or more Which of the following is characteristic of manic episodes associated with bipolar disorder (BD) 1 but NOT hypomanic episodes associated with BD2? No marked impairment is seen in the patient The episode lasts fewer than 4 days nearly every day for most of the day The episode lasts at least 7 days nearly every day for most of the day There is a chance in functioning seen in the patient and observable by others According to a DBSA survey, which of the following side effects was the most commonly cited reason for discontinuing BD medication? Anhedonia Anxiety Sexual Dysfunction Weight gain According to a 6-month open label extension trial, lumateperone demonstrated no clinically significant changes in____________ from baseline to end of treatment. Cardiometabolic measures Development of anxiety Nausea and gastrointestinal dysfunction Somnolence/sedation Lumateperone has demonstrated safety and efficacy for the treatment of BD-1 and BD-2. Which of the following best describes lumateperone’s MOA? High-affinity dopamine receptor antagonism Low-affinity dopamine receptor agonism High-affinity serotonin 2A (5HT-2A) receptor antagonism Low-affinity serotonin 2A (5HT-2A) receptor antagonism How confident are you in your ability to incorporate appropriate evidence-based, patient-centered strategies for BD management to improve treatment outcomes and patient QoL? Very confident Confident Somewhat confident Not very confident Not at all confident Based on my participation in this activity, I anticipate I will more often: (select all that apply) Differentiate between symptom domains in patients with BD, as well as BD-I, BD-II, and MDD Screen for past manic or hypomanic episodes in all patients with depressive symptoms Assess the impact of AEs on patient outcomes and treatment adherence Utilize novel treatment options with a lower potential for weight gain and metabolic adverse effects in BD-1 and BD-2 Switch patients with weight/metabolic problems on their current treatment to a novel agent with an improved weight/metabolic profile Utilize patient-centered strategies for BD management to improve patient outcomes and QoL Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Previous
